Zug, Switzerland-based vVardis, a dental medtech company, has filed for a U.S. initial public offering, according to an Oct. 9 report from Investing.com.
The company reported a net loss of $27.8 million on revenue of $28.6 million for the first six months of 2026, a significant improvement on its reported net loss of $32.1 million on revenue of $9.1 million in the first half of 2025.
Since launching commercially in the U.S., vVardis products have been sold to more than 20,000 dentists.
The company received a minority investment from Apollo Funds in April 2026.
After the IPO, founders Haley Abivardi, DMD, and Goly Abivardi, DMD, will maintain majority shareholder voting power, the release said.
